Cargando…

Targeting lipid metabolism in metastatic prostate cancer

Despite key advances in the treatment of prostate cancer (PCa), a proportion of men have de novo resistance, and all will develop resistance to current therapeutics over time. Aberrant lipid metabolism has long been associated with prostate carcinogenesis and progression, but more recently there has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheinberg, Tahlia, Mak, Blossom, Butler, Lisa, Selth, Luke, Horvath, Lisa G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893394/ https://www.ncbi.nlm.nih.gov/pubmed/36743527 http://dx.doi.org/10.1177/17588359231152839

Ejemplares similares

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin
por: Mak, Blossom, et al.
Publicado: (2022)

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase
por: Lin, Hui-Ming, et al.
Publicado: (2021)

IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor
por: Carter, Sarah Louise, et al.
Publicado: (2016)

Erratum to: IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor
por: Carter, Sarah L., et al.
Publicado: (2016)

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
por: Scheinberg, Tahlia, et al.
Publicado: (2020)

Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play
por: Sapre, Nikhil, et al.
Publicado: (2013)

Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer
por: Xie, Jianling, et al.
Publicado: (2021)

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
por: Mak, Blossom, et al.
Publicado: (2022)

Data Mining of Small RNA-Seq Suggests an Association Between Prostate Cancer and Altered Abundance of 5′ Transfer RNA Halves in Seminal Fluid and Prostatic Tissues
por: Dhahbi, Joseph M, et al.
Publicado: (2018)

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
por: Lin, Hui-Ming, et al.
Publicado: (2021)

Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer
por: Hinneh, Josephine A., et al.
Publicado: (2023)

Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
por: Pardo, Juan C., et al.
Publicado: (2022)

Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants
por: Centenera, Margaret M., et al.
Publicado: (2022)

Circulating microRNAs predict biochemical recurrence in prostate cancer patients
por: Selth, L A, et al.
Publicado: (2013)

Targeting the Metabolic Adaptation of Metastatic Cancer
por: Tarragó-Celada, Josep, et al.
Publicado: (2021)

Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor’s Immune Environment
por: Siltari, Aino, et al.
Publicado: (2022)

Alteration of Lipid Metabolism in Prostate Cancer: Multifaceted Oncologic Implications
por: Zeković, Milica, et al.
Publicado: (2023)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Targeting lipid metabolism in the treatment of ovarian cancer
por: Chaudhry, Saliha, et al.
Publicado: (2022)

Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy
por: Stoykova, Gergana E., et al.
Publicado: (2019)

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)
por: Conduit, Ciara, et al.
Publicado: (2022)

A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer
por: Matin, Farhana, et al.
Publicado: (2018)

Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer
por: Somanath, Payaningal R., et al.
Publicado: (2023)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
por: Mollica, Veronica, et al.
Publicado: (2021)

Targeted Approaches in Metastatic Castration-Resistant Prostate Cancer: Which Data?
por: Mosillo, Claudia, et al.
Publicado: (2022)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2020)

Targeting Mitochondrial Metabolism in Prostate Cancer with Triterpenoids
por: Mamouni, Kenza, et al.
Publicado: (2021)

Precision Nutrition for Targeting Lipid Metabolism in Colorectal Cancer
por: Aguirre-Portolés, Cristina, et al.
Publicado: (2017)

Lipid metabolism reprogramming and its potential targets in cancer
por: Cheng, Chunming, et al.
Publicado: (2018)

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
por: Chan, Siu Chiu, et al.
Publicado: (2015)

Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis
por: Nassar, Zeyad D, et al.
Publicado: (2020)

Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges
por: Sorrentino, Carlo, et al.
Publicado: (2023)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Immunotherapy in metastatic prostate cancer
por: Slovin, Susan F.
Publicado: (2016)

BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
por: Fettke, Heidi, et al.
Publicado: (2023)

Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion
por: Armstrong, Heather K., et al.
Publicado: (2018)

Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors
por: Zeng, Xianhu, et al.
Publicado: (2021)

Systemic treatment for metastatic prostate cancer
por: Gravis, Gwenaelle
Publicado: (2019)

MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4
por: Wang, Qingqing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ibfivinfs2rkf8svckcuvec7s